general manager of Novo Nordisk UK. "Our smart connected insulin pens aim to empower people to better understand their diabetes management, have more informed conversations with their doctor and ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

Novo Nordisk A/S, together with its subsidiaries ... The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes ...

“Unfortunately, the complexities of the U.S. health care system can reduce access and affordability for many,” Jamie Bennett, a spokeswoman for Novo Nordisk, which makes Victoza, said in a ...

Since the 1990s, Novo Nordisk has operated a facility in Clayton, where it makes injectable finished products like insulin pens to treat diabetes. In the past few years however, the company has ...

The insulins available without a prescription come in vials and pens that may need ... teamed up with drugmaker Novo Nordisk to sell its own brand, called ReliOn insulin, which sells for as ...

The insulin delivery pen industry is a competitive landscape where the key players compete to acquire market dominance. Some leaders include Novo Nordisk, Eli Lilly, and Sanofi. These companies in the ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.